MANGOCEUTICALS, INC. Files 8-K: Equity Sales, Officer Changes, Financials
Ticker: MGRX · Form: 8-K · Filed: Feb 7, 2025 · CIK: 1938046
| Field | Detail |
|---|---|
| Company | Mangoceuticals, INC. (MGRX) |
| Form Type | 8-K |
| Filed Date | Feb 7, 2025 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.0001, $105,000, $1.50, $180,000, $15,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: equity-sale, corporate-governance, financials
TL;DR
MANGOCEUTICALS, INC. filed an 8-K detailing equity sales, board/officer changes, and financial statements.
AI Summary
On February 3, 2025, MANGOCEUTICALS, INC. reported on several key events. The company disclosed unregistered sales of equity securities and announced changes in its board and officer composition, including director departures and elections, along with updates to compensatory arrangements for certain officers. The filing also included financial statements and exhibits.
Why It Matters
This 8-K filing provides crucial updates on MANGOCEUTICALS, INC.'s corporate governance and financial activities, which could impact investor confidence and stock valuation.
Risk Assessment
Risk Level: medium — The filing involves unregistered equity sales and changes in corporate leadership, which can introduce uncertainty and potential risks for investors.
Key Numbers
- 001-41615 — SEC File Number (Identifies the company's filing history with the SEC.)
- 87-3841292 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- MANGOCEUTICALS, INC. (company) — Registrant
- February 3, 2025 (date) — Date of Earliest Event Reported
- Texas (location) — State of Incorporation
- Dallas (location) — Principal Executive Offices City
- 75248 (postal_code) — Principal Executive Offices Zip Code
FAQ
What type of equity securities were sold and under what terms?
The filing indicates 'Unregistered Sales of Equity Securities' but does not provide specific details on the type or terms of these sales in the provided text.
Who are the specific officers or directors that departed or were elected?
The filing mentions 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers' but does not name the individuals involved in the provided text.
What are the details of the compensatory arrangements for certain officers?
The filing notes 'Compensatory Arrangements of Certain Officers' but does not specify the nature or value of these arrangements in the provided text.
What specific financial statements are included in the filing?
The filing lists 'Financial Statements and Exhibits' as an item information, but the specific statements are not detailed in the provided text.
What is the nature of the 'MISC HEALTH & ALLIED SERVICES, NEC' industry classification?
This SIC code (8090) generally covers establishments primarily engaged in providing health and allied services, not elsewhere classified, which can include a variety of specialized health services.
Filing Stats: 993 words · 4 min read · ~3 pages · Grade level 11.9 · Accepted 2025-02-07 17:25:36
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 Par Value Per Share MGRX The Nasdaq
- $105,000 — n stock from the Company for a total of $105,000, $1.50 per share. The Subscription Agre
- $1.50 — om the Company for a total of $105,000, $1.50 per share. The Subscription Agreement i
- $180,000 — Hammer's compensation was increased to $180,000 per year, effective February 1, 2025; a
- $15,000 — greed to pay Ms. Hammer a cash bonus of $15,000 within 30 days of the effective date of
Filing Documents
- form8-k.htm (8-K) — 45KB
- ex10-1.htm (EX-10.1) — 238KB
- ex10-2.htm (EX-10.2) — 34KB
- 0001493152-25-005457.txt ( ) — 536KB
- mgrx-20250203.xsd (EX-101.SCH) — 3KB
- mgrx-20250203_lab.xml (EX-101.LAB) — 33KB
- mgrx-20250203_pre.xml (EX-101.PRE) — 24KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. MANGOCEUTICALS, INC. Date: February 7, 2025 By: /s/ Jacob D. Cohen Jacob D. Cohen Chief Executive Officer